Vertex's Cystic Fibrosis Drug Kalydeco Could See Speedy Review
This article was originally published in The Pink Sheet Daily
Executive Summary
High unmet medical need, a genetically targeted patient population and the drug's biological rationale could combine for a faster-than-six-month approval for the novel, disease-modifying therapy.